Welcome to PGIM. This page is intended for Borrowers. Change your role here.
You are attested as an Institutional Investor, but this page is intended for a Borrower. Change your role here.
You are attested as a Financial Advisor / Intermediary, but this page is intended a Borrower. Change your role here.
You are attested as an Individual Investor, but this page is intended for a Borrower. Change your role here.
You are attested as an Institutional Investor, but this page is intended for a Borrower.
You are attested as a Financial Advisor / Intermediary, but this page is intended a Borrower.
You are attested as an Individual Investor, but this page is intended for a Borrower.
In recent months, GLP-1 drugs have been thrust into the spotlight, amplified by increased media attention and several headline-grabbing comments from large retailers. In this episode of All the Credit®, host Brian Barnhurst, CFA, Co-Head of Credit Research, is joined by U.S. Leveraged Finance Credit Research Analysts, Elizabeth Halpin, CFA, Richard Kus, CFA, and Scott Swanson, CFA, to consider the investment implications of GLP-1s across fixed income markets and industries.
Recorded on December 19, 2023.
This content is investment focused and not intended to be a substitute for professional medical or health advice, diagnosis, or treatment, and does not constitute medical or other professional advice in any form.
Let us help you navigate today's complex market environment.
PGIM appreciates your trust and respects your privacy. We use cookies to improve your experience. You can manage your cookie settings and learn more about how we protect your information at the PGIM Privacy Center .
*This website uses cookies
PGIM appreciates your trust and respects your privacy. We use cookies to improve your experience. You can manage your cookie settings and learn more about how we protect your information at the PGIM Privacy Center .
This field is required.
Loading terms...
Terms and Conditions could not be loaded. Please contact your system administrator.